Targeting of steroid hormone receptor function in breast and prostate cancer

Shilpa Gupta; Douglas Yee

doi:10.1007/978-3-319-44675-2_30

Targeting of steroid hormone receptor function in breast and prostate cancer

Shilpa Gupta, Douglas Yee

Medicine - Hematology, Oncology, Transplant

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Regulation of the normal breast and prostate epithelial cells by steroid hormones has provided important insight into the control of malignant cells derived from these tissues. Over many years, strategies to disrupt ligand levels and block hormone binding to the estrogen receptor and androgen receptor have led to improved outcomes for breast and prostate cancer. Based on our understanding of hormone receptor function, numerous drugs have been approved for risk reduction, adjuvant therapy, and treatment of metastatic disease. In addition, new strategies are moving forward to further target receptor function by disrupting other signaling inputs. This review will address the current therapies and identify strategies for the future.

Original language	English (US)
Title of host publication	Endocrinology (Switzerland)
Publisher	Springer Science and Business Media Deutschland GmbH
Pages	765-785
Number of pages	21
DOIs	https://doi.org/10.1007/978-3-319-44675-2_30
State	Published - 2018

Publication series

Name	Endocrinology (Switzerland)
ISSN (Print)	2510-1927
ISSN (Electronic)	2510-1935

Bibliographical note

Publisher Copyright:
© Springer International Publishing AG 2018.

Keywords

Androgen receptor
Aromatase
Breast cancer
Estrogen receptor
Lyase
Prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/978-3-319-44675-2_30

OpenUrl availability

Full text

Cite this

@inbook{e350e2d4e5c9424aab4eac84cd0fd39c,

title = "Targeting of steroid hormone receptor function in breast and prostate cancer",

abstract = "Regulation of the normal breast and prostate epithelial cells by steroid hormones has provided important insight into the control of malignant cells derived from these tissues. Over many years, strategies to disrupt ligand levels and block hormone binding to the estrogen receptor and androgen receptor have led to improved outcomes for breast and prostate cancer. Based on our understanding of hormone receptor function, numerous drugs have been approved for risk reduction, adjuvant therapy, and treatment of metastatic disease. In addition, new strategies are moving forward to further target receptor function by disrupting other signaling inputs. This review will address the current therapies and identify strategies for the future.",

keywords = "Androgen receptor, Aromatase, Breast cancer, Estrogen receptor, Lyase, Prostate cancer",

author = "Shilpa Gupta and Douglas Yee",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing AG 2018.",

year = "2018",

doi = "10.1007/978-3-319-44675-2_30",

language = "English (US)",

series = "Endocrinology (Switzerland)",

publisher = "Springer Science and Business Media Deutschland GmbH",

pages = "765--785",

booktitle = "Endocrinology (Switzerland)",

address = "Germany",

}

TY - CHAP

T1 - Targeting of steroid hormone receptor function in breast and prostate cancer

AU - Gupta, Shilpa

AU - Yee, Douglas

N1 - Publisher Copyright: © Springer International Publishing AG 2018.

PY - 2018

Y1 - 2018

N2 - Regulation of the normal breast and prostate epithelial cells by steroid hormones has provided important insight into the control of malignant cells derived from these tissues. Over many years, strategies to disrupt ligand levels and block hormone binding to the estrogen receptor and androgen receptor have led to improved outcomes for breast and prostate cancer. Based on our understanding of hormone receptor function, numerous drugs have been approved for risk reduction, adjuvant therapy, and treatment of metastatic disease. In addition, new strategies are moving forward to further target receptor function by disrupting other signaling inputs. This review will address the current therapies and identify strategies for the future.

AB - Regulation of the normal breast and prostate epithelial cells by steroid hormones has provided important insight into the control of malignant cells derived from these tissues. Over many years, strategies to disrupt ligand levels and block hormone binding to the estrogen receptor and androgen receptor have led to improved outcomes for breast and prostate cancer. Based on our understanding of hormone receptor function, numerous drugs have been approved for risk reduction, adjuvant therapy, and treatment of metastatic disease. In addition, new strategies are moving forward to further target receptor function by disrupting other signaling inputs. This review will address the current therapies and identify strategies for the future.

KW - Androgen receptor

KW - Aromatase

KW - Breast cancer

KW - Estrogen receptor

KW - Lyase

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85164761743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164761743&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44675-2_30

DO - 10.1007/978-3-319-44675-2_30

M3 - Chapter

AN - SCOPUS:85164761743

T3 - Endocrinology (Switzerland)

SP - 765

EP - 785

BT - Endocrinology (Switzerland)

PB - Springer Science and Business Media Deutschland GmbH

ER -

Targeting of steroid hormone receptor function in breast and prostate cancer

Abstract

Publication series

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this